CFT8634 |
| Catalog No.GC65602 |
CFT8634 es un degradador dirigido a BRD9 extraÍdo del compuesto 174 de la patente WO2021178920A1. CFT8634 se puede utilizar para la investigaciÓn de sarcoma sinovial y tumores sÓlidos con eliminaciÓn de SMARCB1.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2704617-96-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CFT8634 is a degrader targeting BRD9 extracted from patent WO2021178920A1 compound 174. CFT8634 can be used for the research of synovial sarcoma and SMARCB1-deleted solid tumors[1].
[1]. Nasveschuk CG, et, al. Compounds for targeted degradation of brd9. WO2021178920A1.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *